17β-estradiol Inhibits the Production of RANTES in Human Keratinocytes  by Kanda, Naoko & Watanabe, Shinichi
ORIGINAL ARTICLE
17b-estradiol Inhibits the Production of RANTES in Human
Keratinocytes
Naoko Kanda and Shinichi Watanabe
Department of Dermatology,Teikyo University, School of Medicine,Tokyo, Japan
A chemokine, regulated upon activation, normal T cell
expressed and secreted (RANTES) attracts T helper-1
cells and macrophages. The production of RANTES is
enhanced in keratinocytes of psoriatic skin lesions,
which may contribute to the in£ammatory in¢ltrate. It
is known that estrogen regulates the natural course of
psoriasis. We examined the in vitro e¡ects of 17b-estra-
diol on RANTES production by human keratinocytes.
17b-estradiol inhibited tumor necrosis factor-a or inter-
leukin-1b-induced RANTES secretion, mRNA expres-
sion, and promoter activity in keratinocytes, and these
e¡ects of 17b-estradiol were counteracted by estrogen
receptor antagonist ICI 182 780. Two nuclear factor jB
elements on RANTES promoter were required for
tumor necrosis factor-a or interleukin-1b-induced
transcription and involved in the inhibition by 17b-
estradiol. 17b-estradiol inhibited nuclear factor jB tran-
scriptional activity, whereas it did not inhibit DNA
binding of nuclear factor jB or phosphorylation or de-
gradation of the inhibitor of nuclear factor jB a in
tumor necrosis factor-a or interleukin-1b-stimulated
keratinocytes. 17b-estradiol-induced inhibition of
nuclear factor jB transcriptional activity and RANTES
promoter activity was rescued by overexpression of a
coactivator cyclic AMP response element-binding
protein (CREB) or nuclear factor jB p65 but not by
steroid receptor coactivator-1 or nuclear factor jB p50.
The overexpression of CREB-binding protein rescued
17b-estradiol-induced inhibition of transcription
mediated by a chimeric protein, GAL4-p65286^551,
which contained GAL4 DNA binding domain fused to
C-terminal transactivating domain of p65 (amino acids
286^551). The transfection of estrogen receptor a or es-
trogen receptor b into estrogen receptor-negative
SKBR3 cells resulted in 17b-estradiol-mediated inhibi-
tion of transcription via GAL4-p65286^551. These results
suggest that 17b-estradiol-bound estrogen receptor may
inhibit nuclear factor jB-dependent transcription of
RANTES gene by competing with p65 for limiting
amounts of CREB-binding protein. Key words: CREB
binding protein/nuclear factor kB/psoriasis. J Invest Dermatol
120:420 ^427, 2003
P
soriasis is characterized by epidermal hyperplasia asso-
ciated with vascular proliferation and in£ammatory
in¢ltrates composed of T cells, macrophages, or neu-
trophils (Bos and de Rie, 1999). Such in¢ltrates may
be attributable to the increased expression of various
chemokines by lesional keratinocytes (Giustizieri et al, 2001). The
lymphocytes in¢ltrating into psoriatic lesions are predominantly
activated T helper-1 cells (Uyemura et al, 1993; Bos and de Rie,
1999). CXC-chemokines, interferon-induced protein of 10 kDa,
and monokines induced by interferon-g, are thought to be pri-
mary chemokines attracting T helper-1 cells into psoriatic lesions
(Giustizieri et al, 2001). A CC-chemokine, regulated upon activa-
tion, normal T cell expressed and secreted (RANTES), also pre-
ferentially attracts T helper-1 cells rather than T helper-2 cells
(Siveke and Hamann, 1998). It is reported that RANTES produc-
tion by keratinocytes is increased in psoriatic skin lesions (Fukuo-
ka et al, 1998; Raychaudhuri et al, 1999). RANTES may thus
contribute to theT helper-1-dominant in¢ltration in psoriatic le-
sions as well as CXC-chemokines. RANTES also recruits
macrophages (Ying et al, 1995). T helper-1 cells or macrophages
in¢ltrating into psoriatic lesions in turn may produce RANTES
(Schrum et al, 1996) and proin£ammatory cytokines such as tu-
mor necrosis factor (TNF)-a, interleukin (IL)-1b, or interferon-
g (Uyemura et al, 1993), which promote RANTES production by
keratinocytes (Fukuoka et al, 1998). Thus RANTES production in
psoriatic lesions may be regulated in an autocrine/paracrine man-
ner, which may amplify the in£ammation in the lesions. The
blockage of RANTES production by keratinocytes is a key ther-
apeutic target for psoriasis.
It has been suggested that estrogen may regulate the natural
course of psoriasis (Farber and Nall, 1974; Dunna and Finlay,
1989; Stevens et al, 1993; Boyd et al, 1996; Boyd and King, 1999);
however, the reports are somewhat con£icting; psoriasis improves
during pregnancy, whereas it worsens after delivery (Farber and
Nall, 1974; Dunna and Finlay, 1989; Boyd et al, 1996) or at meno-
pause (Mowad et al, 1998), indicating the protective e¡ects of
estrogen. In contrast, psoriasis £ares premenstrually, and anti-es-
trogen tamoxifen improves the symptoms (Stevens et al, 1993;
Boyd and King, 1999), indicating the disease-accelerating e¡ect
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of estrogen. Such discrepancy may be caused by the diversity in
the immunomodulatory e¡ects of estrogen. Estrogen has both
anti-in£ammatory and pro-in£ammatory functions; 17b-estradiol
(E2) enhances the production of proin£ammatory interferon-g
and anti-in£ammatory IL-10 in T cells (Correale et al, 1998). The
e¡ects of E2 also di¡er with its concentration; antigen-stimulated
TNF-a production in CD4þ T cells was enhanced by 20^40 nM
of E2 but was inhibited by 200^400 nM of E2 (Gilmore et al,
1997). The balance of such diverse functions of estrogen may de-
termine its total e¡ect on the course of psoriasis. Estrogen exerts
its e¡ects via intracellular estrogen receptor (ER); estrogen-
bound ER upregulates or downregulates the transcription of var-
ious genes by binding to the estrogen response element of the
genes or by interacting with other transcription factors (Beato,
1989; Paech et al, 1997). ER exists as two subtypes, ERa and
ERb, encoded by separate genes (Mendelsohn and Karas, 1999).
It has recently been reported that estrogen treatment in vivo in-
hibited RANTES production in murine liver, spinal cord, and
spleen (Matejuk et al, 2001, 2002; Evans et al, 2001). This suggests
that E2 may prevent the in¢ltration of T helper-1 cells or macro-
phages and thus suppress the in£ammation mediated by these
cells in the respective tissues; however, it has been not precisely
examined how E2 inhibits RANTES production in these tissues.
Besides it is unknown if such an inhibitory e¡ect of E2 may oc-
cur in the skin. In this study, we examined if E2 may in vitro in-
hibit RANTES production by human keratinocytes in order to
test the preventive e¡ect of E2 on the development of psoriatic
skin lesions.We found that E2 inhibited TNF-a or IL-1b-indu-
ced RANTES production by suppressing the activity of nuclear
factor (NF)-kB.
MATERIALS AND METHODS
Reagents E2 was purchased from Sigma (St Louis, MO). ICI 182 780
was from Wako Pure Chemical Industries (Osaka, Japan). Recombinant
human TNF-a and IL-1b were purchased from R&D (Minneapolis,
MN). Antibodies used in the electrophoretic mobility shift assay,
immunoprecipitation, and immunoblotting were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA), except for rabbit IgG antibody
against phosphorylated inhibitor of NF-kB (IkB) a (Calbiochem, La
Jolla, CA).
Culture of normal human epidermal keratinocytes Human
neonatal foreskin keratinocytes were cultured in serum-free keratinocyte
growth medium (Clonetics, Walkersville, MD) consisting of basal
medium MCDB153 supplemented with 0.5 mg hydrocortisone per ml, 5
ng epidermal growth factor per ml, 5 mg insulin per ml, and 0.5% bovine
pituitary extract. The cells in the third passage were used for the
experiments.
Measurement of RANTES secretion Keratinocytes (2104 per well)
were seeded in triplicate into 24-well plates in 1 ml keratinocyte growth
medium, adhered overnight, then the medium was changed to basal
keratinocyte basal medium depleted of phenol red, hormones, growth
factors, and bovine pituitary extract, and incubated for 24 h. The medium
was removed and the cells were preincubated with E2 in phenol red-free
keratinocyte basal medium for 10 min, then incubated with TNF-a or IL-
1b in the presence of E2 for another 48 h. The supernatants were assayed
for RANTES by enzyme-linked immunosorbent assay (Biosource,
Camarillo, CA). The sensitivity of the assay was 3 pg per ml.
Reverse transcription^polymerase chain reaction (reverse transcription^
PCR) Keratinocytes were incubated as above for 6 h, and RNA was
extracted using mRNA puri¢cation kit (Pharmacia, Uppsala, Sweden)
according to the manufacturer’s instructions. cDNAwas made from RNA
samples as described (Tjandrawinata et al, 1997). Primers for ampli¢cation
and the sizes of respective PCR products were as follows: RANTES, 50 -
ACCACACCCTGCTGCTTTGCCTACATTGCC-30 (sense) and 50 -
CTCCCGAACCCATTTCTTCTCTGGGTTGGC-30 (anti-sense) for 162
bp; and glyceraldehyde-3-phosphate dehydrogenase, 50 -CCACCCATGG-
CAAATTCCATGGCA-30 (sense) and 50 -TCTACAC-GGCAGGTC-
AGGTCCACC-30 (anti-sense) for 600 bp (Hu et al, 1999). PCR was
performed by one denaturing cycle of 951C for 3 min, 35 cycles
of denaturation at 951C for 30 s, annealing at 581C for 30 s, and extension
at 721C for 30 s, and a ¢nal extension at 721C for 3 min. The PCR
products were analyzed by electrophoresis on 2.5% agarose gels and
stained with ethidium bromide, viewed by ultraviolet light, and
photographed. Densitometric analysis was performed by scanning the
bands into Photoshop and performing densitometry with NIH Image
Software.
Plasmids A ¢re£y luciferase reporter plasmid driven by human
RANTES promoter (^397/þ5 bp relative to the transcriptional start site),
denoted as pRANTES-luc, was constructed by PCR and insertion into
pGL3 basic vector (Promega, Madison, WI) as described (Lin et al, 1999;
Genin et al, 2000). Site-speci¢c mutations were created by multiple rounds
of PCR using appropriate primers with altered bases as described
(Moriuchi et al, 1997). A chloramphenicol acetyl transferase (CAT) reporter
plasmid driven by human IL-8 promoter (^98/þ44 bp relative to the
transcriptional start site), denoted as pIL-8-CAT, was constructed as
described (Kanda and Watanabe, 2001). p3xNF-kB1-SV-luc and p3xNF-
kB2-SV-luc were constructed by inserting three copies of distal NF-kB
(NF-kB1) (50 -ATTTTGGAAACTCCCCTTAGG-30, with consensus sequences
underlined), proximal NF-kB (NF-kB2) (50 -TTGAGGGGATGCCC-
CTAAGG-30) from human RANTES promoter in front of heterologous
minimal SV40 promoter upstream of ¢re£y luciferase reporter as
described (Ohmori et al, 1994). pFR-luc (Stratagene, La Jolla, CA) contains
¢ve copies of the sequences for GAL4 DNA binding sites in front of TATA
box upstream of ¢re£y luciferase reporter. pGAL4-p65286^551 expresses a
chimeric protein containing GAL4 DNA binding domain and C-terminal
region (amino acids 286^551) of p65 and was constructed as described
(Schmitz and Baeuerle, 1991). pCMV-CBP and pCMV-SRC-1 express
full-length CREB-binding protein (CBP) and steroid receptor
coactivator-1 (SRC-1), respectively and were constructed as described
(Kamei et al, 1996; Na et al, 1998). pCMV-p65 and pCMV-p50 express full-
length NF-kB p65 and p50, respectively, and were constructed as described
(Stein et al, 1993). pCMV-ERa and pCMV-ERb expressing full-length
human ERa (595 amino acids) and ERb (530 amino acids), respectively,
were constructed as described (Bhat et al, 1998).
Transfections Transient transfections were performed with E¡ectene
(Qiagen, Tokyo, Japan) as described (Zellmer et al, 2001). Keratinocytes
were plated in 10 cm dishes and grown to about 80% con£uence.
Twenty-four hours before the transfection, the medium was changed to
phenol red-free KBM. Keratinocytes in KBM were incubated for 6 h
with 5 mg of pRANTES-luc, pIL-8-CAT, or p3xNF-kB-SV-luc and 1 mg
of Rous sarcoma virus b-galactosidase vector (pRSV-bgal) with or
without 0.5, 1, or 2.5 mg pCMV-CBP or pCMV-SRC-1 or 1 mg pCMV-
p65 or pCMV-p50, premixed with enhancer, transfection bu¡er, and
E¡ectene. The total amount of plasmid DNA in all samples was made up
to 10 mg with empty CMV vector. The transfected cells were washed and
incubated in KBM for 18 h, then treated with E2 for 10 min prior to the
addition of TNF-a or IL-1b. After 24 h, cell extracts were prepared and
luciferase activities were quanti¢ed using luciferase assay system
(Promega). The same cell extracts were assayed for b-galactosidase activity
using chemiluminescent Galacto-Light kit (Tropix, Bedford, MA). All
readings were taken using a Lumat 9501 luminometer (Berthold,
Wildbach, Germany). The results obtained in each transfection were
normalized for b-galactosidase activity and expressed as relative luciferase
activity. CAT expression was analyzed by CAT-ELISA (Roche
Diagnostics,Tokyo, Japan) for the lysates of the cells transfected with pIL-
8-CAT in place of luciferase reporter vectors, and the results were also
normalized for b-galactosidase activity. In the chimeric protein-mediated
transcription experiments, keratinocytes were transfected with 2.5 mg
pFR-luc and 0.5 mg pRSV-bgal, 2.5 mg pGAL4-p65286^551, with or
without 0.5, 1, or 2.5 mg pCMV-CBP. The total amount of plasmid DNA
was made up to 10 mg with empty vector DNA. Human breast carcinoma
SKBR3 cells (ERa and ERb negative) (Dainippon) were maintained with
1:1 mixture of Dulbecco minimal Eagle’s medium/Ham’s F-12 medium
supplemented with 10% fetal bovine serum. SKBR3 cells were
transfected with 2.5 mg pFR-luc and 0.5 mg pRSV-bgal, 2.5 mg pGAL4-
p65286^551, with or without 1 mg pCMV-ERa or pCMV-ERb, 2.5 mg
pCMV-CBP using E¡ectene in serum, and phenol red-free Dulbecco
minimal Eagle’s medium/F-12 (1:1). The total amount of plasmid DNA
was made up to 10 mg with empty vector.
EMSA The probes used were annealed double-stranded DNA
containing NF-kB2 or NF-kB1 sequences from the human RANTES
promoter. The probes were labeled by incorporation of [32P]deoxycytidine
triphosphate with Klenow DNA polymerase. For gel shift assays, 2^5 mg
of nuclear protein extracts were incubated at room temperature for
5 min with a mixture containing 6 mM HEPES (pH 7.9), 0.4 mM
ethylenediamine tetraacetic acid, 125 mM KCl, 10% glycerol, 0.05 mg per
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ml poly(dI-dC), 1 mM dithiothreitol, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg aprotinin per ml,
and 50 mg leupeptin per ml. Approximately, 1 ng labeled probe was added
and the reactions were incubated at room temperature for another 20 min.
In antibody supershift experiments, the nuclear extracts were preincubated
with anti-NF-kB p65 (sc-8008), p50 (sc-8414), or c-Rel (sc-6955) antibody
on ice for 30 min before the addition of probe. Reactions were then
fractionated on a nondenaturing 5% polyacrylamide gel. The gels were
dried and visualized with PhosphorImager (Molecular Dynamics,
Sunnyvale, CA).
Western blotting Keratinocytes were lyzed in lysis bu¡er (20 mM Tris,
pH 8.0, 0.1 M NaCl, 0.5% Nonidet P-40, 1 mM ethylenediamine tetraacetic
acid, 1 mM phenylmethylsulfonyl £uoride, 1 mg leupeptin per ml, 1 mg
pepstatin per ml, 1 mM dithiothreitol). The lysates were centrifuged
(8000 g, 5 min) and the protein concentration of the supernatants was
determined by Bio-Rad protein assay reagents (Bio-Rad, Hercules, CA).
Twenty micrograms of total cellular protein was electrophoresed by
sodium dodecyl sulfate^polyacrylamide gel electrophoresis and transferred
to a nitrocellulose membrane. The membrane was blocked and incubated
with 1 mg per ml of mouse anti-inhibitor of NF-kB (IkB) a (sc-1643) or
rabbit anti-phospho IkBa antibody (Calbiochem, La Jolla, CA), then
incubated with horseradish peroxidase-conjugated goat anti-mouse IgG
(sc-2005) or horseradish peroxidase-conjugated goat anti-rabbit IgG (sc-
2301), respectively, and developed by enhanced chemiluminescence
(Amersham). Immunoblots for ERwere similarly performed using rabbit
anti-ERa (sc-7207) or anti-ERb (sc-8974) antibody and horseradish
peroxidase-conjugated goat anti-rabbit IgG.
Immunoprecipitation and immunoblotting Whole cell extracts were
prepared from keratinocytes in lysis bu¡er (50 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM ethylenediamine tetraacetic acid, 1 mM Na3VO4, 20 mM b-
glycerol phosphate, 1 mM phenylmethylsulfonyl £uoride, 1 mg leupeptin
per ml, 2 mg aprotinin per ml, 1 mg pepstatin per ml, 1% Nonidet P-40,
0.25% deoxycholate, and 0.1% sodium dodecyl sulfate). Extracts were
immunoprecipitated with 10 mg per ml of anti-NF-kB p65 or p50
antibodies. The immune complexes were captured on protein G-
Sepharose beads (Pharmacia, Piscataway, NJ) for 1 h at 41C. Precipitated
proteins were washed by lysis bu¡er and were separated by sodium
dodecyl sulfate^polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane. The membrane was blocked and incubated with
1 mg per ml of anti-ERb antibody, then incubated with horseradish
peroxidase-conjugated secondary antibody, and developed. Following the
analysis of ERb, the blots were stripped and reprobed with anti-p65 or
anti-p50 antibodies as described above. The same cell extracts were also
immunoprecipitated with anti-ERb antibody, then immunoblotted with
anti-p65 or p50 antibodies as described above.
RESULTS
Keratinocytes express ERb, but not ERa The presence of
ER subtypes was analyzed by western blot (Fig 1). A 55 kDa
band for ERbwas detected (lane 4) but 66 kDa band for ERa
was not detected (lane 2) in human keratinocytes. These results in
western blot were consistent with those in immunohistochemical
studies,1 and indicate that E2 may act by binding to ERb in
human keratinocytes.
E2 inhibits RANTES secretion induced by TNF-a or
IL-1b The constitutive RANTES secretion with medium
alone was minimal in keratinocytes (mean7SEM 1573 pg per
ml, n¼ 5), and TNF-a 50 ng per ml or IL-1b 50 U per ml
enhanced the RANTES secretion up to 310732 pg per ml or
248721 pg per ml (n¼ 5), respectively. Though E2 did not alter
the constitutive RANTES secretion, it suppressed TNF-a or IL-
1b-induced RANTES secretion (Fig 2a); the signi¢cant e¡ect
of E2 occurred at 1010 M, and increased in a concentration-
dependent manner and maximized at 108 M, which inhibited
the TNF-a or IL-1 b-induced RANTES secretion by 75% or
72%, respectively. Though ER antagonist ICI 182 780 alone did
not alter TNF-a or IL-1b-induced RANTES secretion in the absence of E2, it counteracted the E2-mediated inhibition on
TNF-a or IL-1b-induced RANTES secretion (Fig 2b),
indicating that the e¡ects of E2 may be mediated via ER. We
then examined if E2 may inhibit RANTES mRNA expression
induced byTNF-a or IL-1b.
Figure1. Western blot analysis for ER subtypes in keratinocytes.The
whole cell lysates from keratinocytes (KC) (lanes 2 and 4) were analyzed for
the expression of ERa (lanes 1 and 2) and ERb (lanes 3 and 4). The positive
controls (Con) (lanes 1 and 3) were the lysates from breast cancer MCF-7
cells. The results shown in the ¢gure are representative of ¢ve separate
experiments.
Figure 2. Dose dependency for the e¡ects of E2 on TNF-a- or IL-
1b-induced RANTES secretion in human keratinocytes (a) and the
reversal by ER antagonist on the e¡ects of E2 (b). (a) Human kerati-
nocytes were preincubated with indicated concentrations of E2 for 10 min,
then incubated with 50 ng TNF-a per ml or 50 U per ml IL-1b in the
presence of E2. After 48 h, the culture supernatants were assayed for
RANTES secretion. Values are mean7SD of triplicate cultures. npo0.05
vs control cultures without hormones, by one-way analysis of variance (AN-
OVA) with Dunnett’s multiple comparison test. The data shown in the ¢g-
ure are representative of ¢ve separate experiments. (b) Keratinocytes were
preincubated for 10 min with 108 M E2, 106 M ICI 182 780 (ICI), alone
or in combination, then incubated with 50 ng TNF-a per ml or 50 U per
ml IL-1b for another 48 h.Values are mean7SEM (n¼ 5). npo0.05 vs con-
trol values with medium alone, wpo0.05 vs values with TNF-a alone,
zpo0.05 vs values with TNF-a plus E2, y, po0.05 vs values with IL-1b
alone, zpo0.05 vs values with IL-1b plus E2, by one-way ANOVA with
Sche¡e’s multiple comparison test.
1Thornton MJ,Taylor AH, Mulligan K, Al-Azzawi F: Estrogen receptor
beta is present in the hair follicle and sebaceous gland in male human skin.
J Invest Dermatol 114:351, 2000 (Abstr.)
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E2 inhibits RANTES mRNA expression induced by TNF-a
or IL-1b Though E2 alone did not alter RANTES mRNA
level in unstimulated keratinocytes, E2 suppressed TNF-a or IL-
1b-induced RANTES mRNA expression by 67% or 65% of
control, respectively (Fig 3). ICI 182 780 counteracted the E2-
mediated inhibition on TNF-a or IL-1b-induced RANTES
mRNA expression. Thus E2 inhibited TNF-a- or IL-1b-
induced RANTES production at pretranslational level.We then
examined if E2 may suppress RANTES promoter activity
induced byTNF-a or IL-1b.
E2 inhibits RANTES promoter activity induced by TNF-a
or IL-1b We transiently transfected human RANTES
promoter-luciferase reporter constructs into keratinocytes, and
the promoter activity was assessed by the relative luciferase
activities of the cell lysates. TNF-a increased wild-type
RANTES promoter activity 9.3-fold of controls (Fig 4b,
uppermost three columns), and E2 suppressed the response to
TNF-a by 71% (Fig 4b), and the e¡ect of E2 was counteracted
by ICI 182 780 (data not shown). IL-1b also increased wild-type
RANTES promoter activity 8.5-fold of controls, which was
suppressed by E2 by 65%.
RANTES promoter contains a number of putative cis-acting
elements that may contribute to the promoter activity (Moriuchi
et al, 1997) (Fig 4a).We thus examined which of these elements
may be responsible for the inhibition by E2 on the TNF-a
or IL-1b-induced RANTES transcription, using mutated
promoters. The mutation of NF-kB2 (proximal NF-kB) or NF-
kB1 (distal NF-kB) reduced the basal promoter activity and fold
induction by TNF-a (Fig 4b, the second and third three
columns), and the mutation of both NF-kB elements
completely abrogated the induction by TNF-a of RANTES
promoter and the suppression by E2 on the response to TNF-a
(Fig 4b, the fourth three columns). These results suggest that two
NF-kB elements are necessary for TNF-a-induced promoter
activation and may be involved in the suppression by E2 on the
response to TNF-a. When NF-IL-6, interferon-stimulated
response element, or activator protein-1 element was mutated,
the basal promoter activity, the response to TNF-a, and the
suppression by E2 on the response to TNF-a were not altered
(Fig 4b, ¢fth, sixth, and seventh three columns), indicating that
these elements may not be required for TNF-a-induced
RANTES transcription and may not be involved in the
suppression by E2 on the response to TNF-a. The results were
similar in IL-1b-stimulated keratinocytes (data not shown). We
then analyzed if E2 may suppress NF-kB transcriptional activity
induced byTNF-a or IL-1b.
E2 inhibits NF-jB transcriptional activity induced byTNF-
a or IL-1b Keratinocytes were transiently transfected with
plasmid containing three repeats of NF-kB2 or NF-kB1
sequences linked to the heterologous minimal SV40 promoter
and luciferase reporter, and were incubated with E2 together
with TNF-a. TNF-a increased the NF-kB2 or NF-kB1-
dependent transcriptional activity, and E2 suppressed the
response to TNF-a by 74% or by 72% of controls, respectively
(Fig 5, ¢rst and second four columns). ICI 182 780 counteracted
the E2-mediated inhibition on NF-kB2 or NF-kB1-dependent
transcriptional activity induced by TNF-a. IL-1b also enhanced
NF-kB2 or NF-kB1-dependent transcriptional activity by 10.2-
fold or 10.1-fold of controls, respectively, and these were also
reduced by E2 by 68% or 66%, respectively.We then examined
if E2 may suppress the TNF-a or IL-1b-induced DNA binding
of NF-kB.
Figure 3. The e¡ects of E2 on TNF-a- or IL-1b-induced RANTES
mRNA expression in human keratinocytes. Keratinocytes were prein-
cubated with 10^8 M E2, 10^6 M ICI 182 780 (ICI), alone or in combination
for 10 min, then incubated with 50 ngTNF-a per ml or IL-1b 50 U per ml
in the presence of hormones for another 6 h. RNA was isolated, and re-
verse transcription^PCR was performed. The intensity of the band for
RANTES was corrected to that for glyceraldehydes-3-phosphoate dehy-
drogenase (GAPDH). The lower graph shows the corrected intensities rela-
tive to that in control cells cultured with medium alone (set as 1.0). The
results shown in the ¢gure are representative of ¢ve separate experiments.
Figure 4. The e¡ects of E2 on TNF-a-induced activities of wild-
type or mutated RANTES promoters in human keratinocytes. (a)
Schematic representation of human RANTES promoter. The locations of
cis-elements are shown with their sequences, and substituted bases for mu-
tation are indicated. The nucleotide positions are relative to the transcrip-
tional start site. ISRE, interferon-stimulated response element; NF-IL-6,
nuclear factor IL-6; AP-1, activator protein-1. (b) Keratinocytes were tran-
siently transfected with wild-type (WT) or mutated human RANTES
promoter linked to luciferase reporter together with b-galactosidase vector,
and preincubated with 108 M E2 for 10 min, then incubated with 50 ng
TNF-a per ml for 24 h. Relative luciferase activities normalized to b-ga-
lactosidase activities were shown. The data are mean7SEM (n¼ 4).Values
at right indicate the fold induction vs basal promoter activity. npo0.05 vs
control values and wpo0.05 vs values with TNF-a alone, by one-way ANO-
VAwith Sche¡e’s multiple comparison test.
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E2 did not alter DNA binding of NF-jB The nuclear
extracts from unstimulated keratinocytes formed a small amount
of DNA^protein complex with the NF-kB2 probe (Fig 6, lane
2), and that was enhanced by TNF-a (Fig 6, lane 3), and the
antibodies against NF-kB p65 and p50 but not anti-c-Rel
antibody supershifted the complex (Fig 6, lanes 5^7), indicating
the presence of p65 and p50, and absence of c-Rel in the
complex. The addition of E2 did not reduce the amount of the
TNF-a-induced complex with NF-kB2 probe (Fig 6, lanes 3
and 4; the band intensity compared with control was 15.1-fold in
TNF-a and 14.5-fold in TNF-a plus E2-treated samples,
respectively). Similar results were obtained using NF-kB1 probe
(data not shown). IL-1b also increased the amounts of DNA^
protein complexes with both NF-kB probes, and those were not
reduced by E2 (data not shown). These results suggest that E2
may not suppress TNF-a- or IL-1b-induced p65/p50 binding to
NF-kB elements.
ERb and NF-jB are not coimmunoprecipitated It is known
that ER can bind to NF-kB p65 or p50 in vitro, which may result
in the repression of NF-kB transactivation (Stein and Yang, 1995;
Ray et al, 1997). To examine a possible direct protein^protein
interaction between ER and NF-kB in intact cells, we
performed coimmunoprecipitation assays on the extracts from
keratinocytes treated with TNF-a plus E2 for 30 min. These cell
extracts precipitated with anti-ERb antibody were positive when
blotted for anti-ERb, but were negative when blotted with anti-
p65 or p50 antibodies. The cell extracts precipitated with anti-p65
or p50 antibodies, which were positive when blotted with anti-
p65 or p50 antibodies, respectively, but were negative when
blotted with anti-ERb antibody. Similar results were obtained
when keratinocytes were incubated with IL-1b plus E2 (data
not shown). Thus speci¢c association between ERb and NF-kB
p65 or p50 in keratinocytes could not be detected by
coimmunoprecipitation.
E2 does not inhibit TNF-a-induced IjBa phosphorylation
or degradation In unstimulated cells, NF-kB p50/p65 is
associated with inhibitory protein IkBa in the cytoplasm, and
certain stimuli induce the serine phosphorylation of IkBa by
IkB kinase, leading to the proteolytic degradation of IkBa and
the release of p50/p65, which results in the nuclear translocation
of p50/p65 and its binding to NF-kB sites on certain genes
(Naumann and Scheidereit, 1994). It is reported that E2
suppressed phorbol myristate acetate-induced IkBa degradation
in ERa-transfected HeLa cells (Sun et al, 1998), or inhibited
lipopolysaccharide-induced IkB kinase activity in human
endothelial cells (Simoncini et al, 2000). We thus examined the
involvement of IkBa in the E2-induced inhibition of NF-kB
transcriptional activity in TNF-a-stimulated keratinocytes or
IL-1b-stimulated keratinocytes. TNF-a-stimulated keratinocytes
showed a rapid decrease and disappearance of IkBa protein
within 30 min, which was associated with IkBa phos-
phorylation within 7.5 min. E2 did not inhibit the TNF-a- or
IL-1b-induced IkBa degradation or phosphorylation (data not
shown). It is thus indicated that IkBa may not be involved in
the E2-mediated inhibition of NF-kB activity.
Overexpression of CBP reverses E2-induced inhibition on
NF-jB transactivation and RANTES, and IL-8 promoter
activities It is known that transcriptional coactivator CBP and
SRC-1 play important parts in NF-kB transactivation (Gerritsen
et al, 1997; Na et al, 1998; Sheppard et al, 1999). CBP binds to p65,
whereas SRC-1 binds to p50, and both cooperatively potentiate
NF-kB-mediated transactivation. These coactivators are also
involved in the transactivation by E2-bound ER through
estrogen response elements on certain genes (Torchia et al, 1998;
Mckenna et al, 1999). It is suggested that E2-bound ER
transrepresses NF-kB by competing with NF-kB for
coactivators (Harnish et al, 2000; Glass and Rosenfeld, 2000;
Speir et al, 2000; Evans et al, 2002). We thus examined if the
supplementation of coactivators may reverse the E2-mediated
inhibition of NF-kB transactivation and RANTES promoter
activity in TNF-a or IL-1b-stimulated keratinocytes. Vectors
expressing the coactivators CBP or SRC-1 were cotransfected
with NF-kB-luciferase reporter or RANTES promoter-
luciferase reporter vector into keratinocytes. Overexpression of
Figure 5. The e¡ect of E2 on TNF-a-induced NF-jB transactiva-
tion. Keratinocytes were transiently transfected with luciferase reporter
plasmids driven by NF-kB2 or NF-kB1 linked to heterologous SV-40
minimal promoter together with b-galactosidase vector. The cells were
preincubated with 108 M E2, 106 M ICI 182 780 (ICI), alone or in combi-
nation, then incubated with 50 ng TNF-a per ml for 24 h. The results are
shown as relative luciferase activities normalized for b-galactosidase activ-
ities, and represent mean7SEM (n¼ 4). Values at right indicate the fold
induction vs basal activity. npo0.05 vs control values with medium alone,
wpo0.05 vs values with TNF-a alone, and zpo0.05 vs values with TNF-a
plus E2, by one-way ANOVAwith Sche¡e’s multiple comparison test.
Figure 6. The e¡ect of E2 on TNF-a-induced NF-jB binding to
DNA. Keratinocytes were preincubated with 108 M E2 for 10 min, then
incubated with 50 ngTNF-a per ml for 30 min, and nuclear extracts were
prepared. The nuclear extracts were incubated with 32P-labeled oligonu-
cleotides containing NF-kB2 from human RANTES promoter. In super-
shift assays, antibodies against transcription factors were incubated for 30
min before the addition of the probe. Arrows indicate the supershifted com-
plexes. The results shown in the ¢gure are representative of four separate
experiments.
424 KANDA ANDWATANABE THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
CBP but not of SRC-1 reversed the E2-mediated repression of
TNF-a-induced NF-kB2 activity (Fig 7a) and RANTES
promoter activity (Fig 7b) in a concentration-dependent
manner. The overexpression of p65 but not of p50 partially
rescued the E2-mediated inhibition of TNF-a-induced NF-kB2
activity and RANTES promoter activity. Similar results were
obtained in NF-kB1 activity (data not shown). Overexpression
of CBP and p65 but not of SRC-1 or p50 rescued the E2-
mediated inhibition on IL-1b-induced NF-kB2 or NF-kB1
transcriptional activity and RANTES promoter activity in
keratinocytes (data not shown). These results indicate that E2-
bound ER may compete with p65 for binding to coactivator
CBP, and thus repress NF-kB transcriptional activity and NF-
kB-dependent transcription of RANTES in TNF-a-stimulated
keratinocytes or IL-1b-stimulated keratinocytes. E2 also
inhibited NF-kB-dependent transcription of another chemokine
gene, IL-8 by a similar mechanism (Fig 7c). IL-8 promoter (^98/
þ 44 bp) contains NF-kB element (^80/^70), which confers this
promoter induction by TNF-a or IL-1b (Mukaida et al, 1994).
TNF-a (Fig 7c) or IL-1b (data not shown) enhanced IL-8
promoter activity, which was inhibited by E2. The over-
expression of CBP and p65 but not of SRC-1 or p50 rescued
the inhibition by E2 on TNF-a (Fig 7c) or IL-1b (data not
shown)-induced IL-8 promoter activation.
It is known that CBP binds to p65 C-terminal transactivation
domain (amino acids 286^551) (Gerritsen et al, 1997). To examine
the role of C-terminal transactivation domain of p65 in E2-
mediated transrepression, further experiments were performed
using GAL4-p65286^551, a chimeric protein of GAL4 DNA
binding domain fused to p65 transactivation domain. GAL4-
p65286^551-mediated transactivation of a plasmid containing
multiple GAL4-binding sites (pFR-luc) was inhibited by E2
(Fig 8a, lanes 2 and 3) in a manner similar to that of NF-kB
transrepression. E2-mediated inhibition of GAL4-p65286^551
transactivation was counteracted by ER antagonist ICI 182 780
(Fig 8a, lanes 3 and 4). These results suggest that C-terminal
region of p65 is involved in NF-kB transrepression by E2-
bound ER. Furthermore, cotransfection with CBP reversed the
E2-mediated inhibition of transcription by GAL4-p65286^551 in a
concentration-dependent manner (Fig 8a, lanes 5^7). These
results indicate that E2-bound ER may inhibit the transcription
mediated by the C-terminal region of p65 by competing for
limiting amounts of CBP. To test this hypothesis further, we
examined if ER transfection into ER-negative cells may result
in E2-mediated inhibition of GAL4^p65286^551 transactivation.
E2 did not inhibit GAL4^p65286^551 transactivation in ER-
negative SKBR3 cells (Fig 8b, lanes 1 and 2). Transfection of
ERa or ERb slightly (10^15%) suppressed GAL4^p65286^551
transactivation in the absence of E2, indicating the ligand-inde-
pendent transrepression by ER as reported previously (Valentine
et al, 2000). E2 signi¢cantly suppressed GAL4^p65286^551 trans-
activation in ERa or ERb-transfected SKBR3 cells (Fig 8b,
lanes 4 and 7), and the suppression was reversed by the
overexpression of CBP (Fig 8b, lanes 5 and 8), suggesting that
E2-bound ERa or ERb may suppress the transcription
mediated by C-terminal region of p65 by competing for
limiting amounts of CBP.
DISCUSSION
This study demonstrated that E2 inhibited TNF-a- or IL-1b-in-
duced RANTES production in keratinocytes by inhibiting NF-
kB transcriptional activity. E2-bound ER may sequester CBP
from binding to NF-kB p65. As human keratinocytes express
ERb and not ERa (Fig 1), the e¡ect of E2 may be mediated by
ERb. It is also reported that E2-bound ERb attenuated IL-1b-
or TNF-a-induced NF-kB transcriptional activity as well as
ERa (Bhat et al, 1998; Quaedackers et al, 2001; Evans et al, 2002).
CBP is associated with RNA polymerase II, and can interact
with TFIIB, a basal transcriptional component (Gerritsen et al,
1997). NF-kB p65 C-terminal transactivation domain (amino
acids 286^551) can bind to both N-terminal (amino acids 1^446)
and C-terminal portions of CBP (amino acids 1892^2441)
(Gerritsen et al, 1997). The presence of two functional NF-kB ele-
ments on the RANTES promoter suggests that both N-terminal
and C-terminal binding sites of CBP may simultaneously inter-
act with p65 molecules bound to di¡erent NF-kB elements,
which may create a highly stable and potent multiprotein tran-
scriptional complex. Thus CBP may play an important part for
NF-kB-dependent RANTES transcription. SRC-1 binds to
NF-kB p50 and coactivates NF-kB-mediated transcription in sy-
nergy with CBP (Na et al, 1998; Sheppard et al, 1999). CBP and
SRC-1 also act as coactivators for E2-bound ER-mediated trans-
activation through an estrogen response element (Torchia et al,
1998; McKenna et al, 1999). E2 binding to ER changes the con-
formation of ER and promotes the recruitment of CBP and
SRC-1 (Torchia et al, 1998; McKenna et al, 1999).
In keratinocytes, E2-bound ER appeared to compete with p65
for binding to CBP, which is likely to occur in the cells whose
CBP levels are limiting (Harnish et al, 2000; Evans et al, 2002).
In contrast to CBP, neither SRC-1 nor p50 rescued the E2-
mediated transrepression of NF-kB, which is consistent with the
study by Cerillo et al (1998), indicating that competition between
p50 and E2-bound ER for SRC-1 may not occur in keratino-
cytes. This is possibly because SRC-1may exist more abundantly
Figure 7. The reversal by CBP on E2-mediated repression of NF-jB activity (a) and RANTES (b) or IL-8 promoter activities (c). Keratino-
cytes were transfected with 5 mg p3xNF-kB2-SV-luc (a), or 5 mg pRANTES-luc (b), or 5 mg pIL-8-CAT (c), together with 1 mg pRSVb-gal, and increasing
concentrations of pCMV-CBP (0.5, 1, 2.5 mg) or pCMV-SRC-1 (0.5, 1, 2.5 mg) or 1 m pCMV-p65 or pCMVp50.The total amount of plasmid DNAwas made
up to 10 mg with empty vector. The cells were preincubated with 108 M E2 for 10 min, then incubated with 50 ngTNF-a per ml in the presence of E2 for
24 h. Luciferase activities or CAT expression of the cell lysates were analyzed and were normalized for b-galactosidase activities.Values are mean7SEM of
¢ve separate experiments. npo0.05 vs control values, wpo0.05 vs values with TNF-a, and zpo0.05 vs values with TNF-a plus E2, by one-way ANOVAwith
Sche¡e’s multiple comparison test.
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than CBP, or because other SRC family proteins such as SRC-2
or SRC-3 can substitute for SRC-1 as a coactivator for ER
(Mckenna et al, 1999). As there also exists the other transcriptional
coactivators common to NF-kB and ER, such as CBP-associated
factor, p/CAF (Sheppard et al, 1999), further studies should exam-
ine the involvement of these coactivators in E2-mediated NF-kB
transrepression.
To date, several di¡erent mechanisms are suggested for E2-in-
duced NF-kB transrepression and which mechanism is used may
depend on cell types and NF-kB-activating stimuli: (i) E2-bound
ER may physically interact with NF-kB and inhibit its DNA
binding (Stein and Yang, 1995; Galien and Garcia, 1997; Ray
et al, 1997); (ii) E2 may inhibit IkBa phosphorylation (Simoncini
et al, 2000); (iii) E2 may inhibit IkBa degradation (Sun et al, 1998)
or increase IkBa protein level (McMurray et al, 2001); or (iv) E2
induces the expression of NF-kB precursor p105, which inhibits
NF-kB nuclear translocation and DNA binding (Hsu et al, 2000).
These possibilities are rather unlikely in keratinocytes, however,
as E2 did not alter IkBa degradation or phosphorylation,
or DNA binding of NF-kB in keratinocytes, and coimmuno-
precipitation assays failed to demonstrate the stable complexes
between ERb and NF-kB.
E2 in vitro inhibited RANTES production in human keratino-
cytes. On the other hand, E2 did not alter RANTES production
in TNF-a plus interferon-g-stimulated human bronchial epithe-
lial cells (Stellato et al, 1995) or human endometrial stromal cells
(Hornung et al, 1997).Wood et al (1997) reported that RANTES
production in murine uterus was enhanced during early preg-
nancy, indicating the stimulatory e¡ect of E2 on RANTES
production. Possibly, the regulation of RANTES production by
E2 may di¡er dependently on cell types or stimuli. The amounts
or activities of CBP, p65, or ER may determine if E2 may inhibit
NF-kB activity. Besides in certain cell types, RANTES promoter
activity may be dependent on transcription factors other than
NF-kB, such as activator protein-1, whose activity may be stimu-
lated by E2-bound ERa (Paech et al, 1997). At least in human
keratinocytes, however, TNF-a- or IL-1b-induced RANTES
transcription was exclusively dependent on NF-kB, and was in-
hibited by E2. This indicates that E2 may suppress the in¢ltration
of T helper-1 cells or macrophages into psoriatic skin lesions by
inhibiting RANTES production in keratinocytes, implicating
the preventive role of E2 in the course of psoriasis.
The serum E2 level is about 1010 M in men, whereas in wo-
men that ranges from about 41010 M in the follicular phase to
2109 M at the time of ovulation, and may rise to nearly
7108 M during pregnancy and fall to values below 1010 M
after menopause (Mendelson and Karros, 1999). In this study, sig-
ni¢cant inhibition of RANTES production by E2 appeared at
1010 M, and increased in a concentration-dependent manner,
and maximized at 108 M (Fig 2). It is thus suggested that E2
may in vivo suppress RANTES production by keratinocytes in
men and women, and the e¡ect may be enhanced with ovulation
or pregnancy, and reduced after menopause in women, which
may be related to the improvement of psoriasis during pregnancy
and its exacerbation at menopause. Furthermore, E2 also inhi-
bited TNF-a- or IL-1b-induced IL-8 promoter activation via
NF-kB inhibition (Fig 7). Psoriatic skin lesions are associated
with focal dense in¢ltration of neutrophils, and the production
of the neutrophil-attracting chemokine, IL-8, is enhanced in ker-
atinocytes of those lesions (Gillitzer et al, 1996). E2 may thus in-
hibit neutrophil in¢ltration into psoriatic lesions by inhibiting
IL-8 production in keratinocytes. These results totally suggest
that E2 may broadly suppressT helper-1-, macrophage-, and pos-
sibly neutrophil-mediated in£ammation in psoriatic skin lesions
by inhibiting the production of chemokines attracting these cells
in keratinocytes. Thus E2 may be therapeutically used for the
treatment of psoriatic patients. We are now studying if E2 may
also suppress the production of other psoriasis-related chemo-
kines such as monocyte chemoattractant protein-1.
This work was supported in part by a grant from Japan Society for the Promotion of
Science (14570825) and an aid from Shiseido.
Figure 8. The e¡ects of E2 on GAL4-p65286^551-mediated transcrip-
tion in keratinocytes (a) and repression of GAL4-p65286^551-
mediated transcription by E2 in ERa or ERb-transfected SKBR3
cells (b). (a) Keratinocytes were transfected with 2.5 mg pFR-luc, 0.5 mg
pRSV-bgal, and 2.5 mg pGAL4-p65286^551with or without increasing con-
centrations of pCMV-CBP (0.5, 1, 2.5 mg). The total amount of plasmid
DNAwas made up to 10 mg with empty vector. The cells were incubated
with or without 108 M E2 in the presence or absence of 106 M ICI 182 780
(ICI) for 24 h. Luciferase activities of the cell lysates were analyzed and
were normalized for b-galactosidase activities. Values are mean7SEM of
¢ve separate experiments. npo0.05 vs values of pGAL4-p65286^551-trans-
fected cells without E2, wpo0.05 vs values of pGAL4-p65286^551-trans-
fected cells incubated with E2, by one-way ANOVA with Sche¡e’s multiple
comparison test. (b) ER-negative SKBR3 cells were transfected with 2.5
mg pFR-luc, 0.5 mg pRSV-bgal, and 2.5 mg pGAL4-p65286^551 with or
without 1 mg pCMV-ERa or pCMV-ERb, 2.5 mg pCMV-CBP. The cells
were incubated with or without 108 M E2 for 24 h and analyzed for rela-
tive luciferase activities as above. Values are mean7SEM of ¢ve separate
experiments. npo0.05 vs control values of empty vector-transfected cells
without E2 treatment, and wpo0.05 vs values of ERa-transfected cells
treated with E2, and zpo0.05 vs values of ERb-transfected cells treated
with E2, by one-way ANOVAwith Sche¡e’s multiple comparison test.
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